Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 301–400 of 662
Choudhary, P., de Portu, S., Arrieta, A., Castañeda, J., & Campbell, F. (2019) · Diabetic Medicine · doi:10.1111/dme.14043 · Cited by 23
Ridder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865399 · Cited by 23
Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring
Kovatchev, B. P. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0144 · Cited by 24
Kłak, A., Mańczak, M., Owoc, J., & Olszewski, R. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16047 · Cited by 27
“The growing body of evidence on efficacy of rtCGM [3-8] led in 2019 the American Diabetes Association (ADA) to recommend the rtCGM to be used daily for maximum results [9].”
BackgroundHypoglycemia During Therapy of Diabetes
Spanakis, E. K., Cryer, P. E., & Davis, S. N. (2015) · Europe PMC (PubMed Central) · Cited by 21
Do youth with type 1 diabetes exercise safely? A focus on patient practices and glycemic outcomes
Roberts, A. J. C., Yi‐Frazier, J. P., Aitken, K. E., Mitrovich, C., Pascual, M., & Taplin, C. E. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12402 · Cited by 22
“Features incorporating CGM data are available on some pumps, such as automatic suspension of basal insulin at a pre-determined hypoglycemia threshold, and have been shown to reduce risk of hypoglycemia (35, 36) overall, and in the exercise state.”
MethodInsulin Therapy in Type 1 Diabetes
Stephens, E. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.016 · Cited by 25
Tumminia, A., Sciacca, L., Frittitta, L., Squatrito, S., Vigneri, R., Le Moli, R., & Tomaselli, L. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s69482 · Cited by 20
Larsson, C. R., Januszewski, A. S., McGrath, R. T., Ludvigsson, J., KEECH, A. C., MacIsaac, R. J., Ward, G. M., O'Neal, D. N., Fulcher, G. R., & Jenkins, A. J. (2018) · Internal Medicine Journal · doi:10.1111/imj.13798 · Cited by 20
Type 1 diabetes: from the dream of automated insulin delivery to a fully artificial pancreas
Phillip, M., Kowalski, A. J., & Battelino, T. (2024) · Nature Medicine · doi:10.1038/d41591-024-00013-5 · Cited by 20
Heinemann, L., Deiss, D., Hermanns, N., Graham, C., Kaltheuner, M., Liebl, A., & Price, D. A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815575999 · Cited by 20
“- The duration for which glucose has to be below the selected threshold was also used in the ASPIRE study.(47) Secondary Endpoints Patients in both study groups will be instructed to document (advanced) hypoglycemic or SH events during the study duration as close as possible; they will be asked to note the date, time,…”
MethodPractical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes
Kreider, K. E., Pereira, K. C., & Padilla, B. I. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0325-9 · Cited by 22
“Starting in 2017, Medicare in the USA will cover CGMs for selected patients [32].”
BackgroundPeters, A. L., Ahmann, A., Hirsch, I. B., & Raymond, J. K. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00262 · Cited by 21
“After the benefit of sensor-augmented pump therapy was demonstrated, the Automation to Simulate Pancreatic Insulin Response (ASPIRE) trial confirmed that integrating CGM with an insulin pump and adding appropriate, computerized, automated decision support could reduce time spent in hypoglycemia with the threshold susp…”
MethodSelf-citationThe Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes
Inoue, R., Nishiyama, K., Li, J., Miyashita, D., Ono, M., Terauchi, Y., & Shirakawa, J. (2021) · Cells · doi:10.3390/cells10071589 · Cited by 23
“Sensor augmented insulin-pump therapy and transplantation therapy of whole pancreas or pancreatic islets may be useful strategies to compensate for β-cell function and control the blood glucose levels [4].”
BackgroundAbraham, M. B., Nicholas, J. A., Ly, T. T., Roby, H. C., Paramalingam, N., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011589 · Cited by 19
Guzmán, G. E., Martínez, V., Yara, J., Mina, M. A., Solarte, J. S., Victoria‐Castro, A. M., & Fériz, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/1581726 · Cited by 19
Cryer, P. E., & Arbeláez, A. M. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch35 · Cited by 26
Pathophysiology and management of hypoglycemia in diabetes
RANGEL, E. S., Deajon-Jackson, J. D., & Hwang, J. J. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14904 · Cited by 21
Acute Metabolic Complications in Diabetes
Rewers, A. (2018) · Europe PMC (PubMed Central) · Cited by 37
Maida, E., Caruso, P., Bonavita, S., Abbadessa, G., Miele, G., Longo, M., Scappaticcio, L., Ruocco, E., Trojsi, F., Esposito, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124240 · Cited by 22
“These technologies initially enabled the glucose-responsive regulation of insulin delivery to address hypoglycemia [46,47].”
Galderisi, A., Schlissel, E., & Cengiz, E. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0944-6 · Cited by 16
Sensor-Augmented Pump-Based Customized Mathematical Model for Type 1 Diabetes
Grosman, B., Wu, D., Miller, D. M., LINTEREUR, L. J., Roy, A., Parikh, N., & KAUFMAN, F. R. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0333 · Cited by 18
Self-citationGómez, A. M., Henao, D. C., Madero, A. I., Múñoz, Ó., Rondón, M., Kattah, L., Guerrero, J. S., Morros-González, E., Llano, J. P., Maira, G., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.03.009 · Cited by 18
Lunati, M. E., Morpurgo, P. S., Rossi, A., Gandolfi, A., Cogliati, I., Bolla, A. M., Plebani, L., Vallone, L., Montefusco, L. B., Pastore, I., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816599 · Cited by 18
“LGS did contribute to a decrease in nocturnal hypoglycemia, but without any significant difference in QOL outcomes (24).”
BackgroundUrakami, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030781 · Cited by 19
“It has been reported that the use of an insulin pump can reduce nocturnal hypoglycemia [79], and this is further reduced by SAP with the control algorithms, which can suspend the basal insulin infusion with sensor-detected [64] or sensor-predicted hypoglycemia [80].”
BackgroundGlycaemic control, glucose variability and the Triangle of Diabetes Care
Rayman, G. A. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.070 · Cited by 19
Insulin Pump Therapy and Continuous Glucose Monitoring
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199568604.001.0001 · Cited by 19
Diabetologische Notfälle: Hypoglykämie, ketoazidotisches und hyperglykämisches Koma
Kalscheuer, H., Serfling, G., Schmid, S. M., & Lehnert, H. (2017) · Der Internist · doi:10.1007/s00108-017-0317-x · Cited by 21
Bally, L., Thabit, H., Tauschmann, M., Allen, J. M., Hartnell, S., Wilinska, M. E., Exall, J., Huegel, V., Sibayan, J., Borgman, S. K., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016738 · Cited by 17
Self-citationDeeb, A., Yousef, H., Qahtani, N. A., Artan, I., Suliman, S., Tomy, M., Abdulrahman, L., Suwaidi, H. A., Attia, S., & Nagelkerke, N. J. D. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0351-9 · Cited by 19
IoTility: Architectural Requirements for Enabling Health IoT Ecosystems
Lindquist, W., Helal, S., Khaled, A. E., & Hutchinson, W. (2019) · IEEE Transactions on Emerging Topics in Computing · doi:10.1109/tetc.2019.2957241 · Cited by 18
“The use of objective sensor data to dictate medication dosing must be undertaken with careful consideration, but has the potential to provide personalized treatment regimens with better safety outcomes [24].”
BackgroundBoughton, C. K., Allen, J. M., Tauschmann, M., Hartnell, S., Wilinska, M. E., Musolino, G., Acerini, C. L., Dunger, D. B., Campbell, F., Ghatak, A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033500 · Cited by 18
Monitoring Glycemia in Diabetes
Healy, S. J., & Dungan, K. M. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.017 · Cited by 22
Price, D. A., & Walker, T. C. (2016) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2016.12.01.24 · Cited by 20
Gómez, A. M., Alfonso‐Cristancho, R., Orozco, J. J., Lynch, P. M., Prieto, D., Saunders, R., Roze, S., & Valencia, J. E. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.05.011 · Cited by 19
Profiling intra-patient type I diabetes behaviors
Contreras, I., Quirós, C., Giménez, M., Conget, I., & Vehı́, J. (2016) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2016.08.022 · Cited by 17
Grosman, B., Wu, D., Parikh, N., Roy, A., Voskanyan, G. R., Kurtz, N., Sturis, J., Cohen, O., Ekelund, M., & Vigersky, R. A. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106087 · Cited by 18
Diabetes Technology: Monitoring, Analytics, and Optimal Control
Kovatchev, B. P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034389 · Cited by 17
“The ASPIRE trial showed a 38% reduction in nocturnal hypoglycemia compared to CGM alone without increasing HbA1c (Bergenstal et al. 2013); a subsequent study achieved similar results (Ly et al. 2013).”
ResultVETTORETTI, M., Chiara, F., Andrea, F., MENEGHETTI, L., Giovanni, S., & Claudio, C. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.2525.abstracts · Cited by 17
Davis, T., Salahi, A., Welsh, J. B., & Bailey, T. S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12542 · Cited by 19
“The primary results [25] showed that routine use of the TS feature was safe, as evidenced by no significant between-group difference in changes in HbA1c, and also that it was effective, as evidenced by a 37.”
ResultSelf-citationEmami, A., Wilinska, M. E., Thabit, H., Leelarathna, L., Hartnell, S., Dellweg, S., Benesch, C., Mader, J. K., Holzer, M., Kojzar, H., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0307 · Cited by 16
Impulsive MPC schemes for biomedical processes: Application to type 1 diabetes
Rivadeneira, P. S., Godoy, J. L., Sereno, J. E., Abuin, P., Ferramosca, A., & González, A. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817461-6.00003-2 · Cited by 20
Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
“Bergenstal et al reported reduced episodes of nocturnal hypoglycaemia without increasing the HbA1c with the use of sensor-augmented closed-loop insulin pump therapy.(66) In patients with diabetes who have hypoglycaemia unawareness, further episodes of hypoglycaemia should be prevented so that the threshold for detecti…”
BackgroundInsulin pumps after injections and CGM in T1DM
Pickup, J. C. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.108 · Cited by 18
Artificial Pancreas Project at Cambridge 2013
Hovorka, R. (2015) · Diabetic Medicine · doi:10.1111/dme.12766 · Cited by 16
Gargallo-Fernández, M., Escalada, J., Peralta, F. G., Moreno, P. R., Martínez, A. M., Botella-Serrano, M., Pérez, C. T., & Fernández, J. L. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.02.004 · Cited by 22
Gómez, A. M., Alfonso‐Cristancho, R., Orozco, J. J., Lynch, P. M., Prieto, D., Saunders, R., Roze, S., & Valencia, J. E. (2016) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2016.10.009 · Cited by 16
Villafuerte, B., Frías, M. M., Martín, M. B. R., Valverde, R. Y., Gómez, M. Á. Á., & Castellanos, R. B. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.02.008 · Cited by 16
Using Flash Continuous Glucose Monitoring in Primary Practice
Hirsch, I. B., & Wright, E. E. (2018) · Clinical Diabetes · doi:10.2337/cd18-0054 · Cited by 15
Zhang, L., Guo, K., Tian, Q., Ye, J., Ding, Z., Zhou, Q., Li, X., Zhou, Z., & Yang, L. (2023) · Nutrients · doi:10.3390/nu15030518 · Cited by 15
“T1D is an organ-specific autoimmune disease in which pancreatic β-cells suffer varying degrees of immune damage, resulting in absolute insulin deficiency and non-negligible GV [1].”
InfluentialDiabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 16
“For example, low glucose suspend is currently available [114] and predicted low glucose suspend is in development [115].”
BackgroundMarin, M. T., Coffey, M. L., Beck, J. K., Dasari, P. S., Allen, R. A., & Krishnan, S. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.176 · Cited by 15
“The ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) study showed reduced nocturnal hypoglycemia without significant differences in A1C when using sensor-augmented insulin pump therapy (SAPT) with a thresholdsuspend…”
BackgroundNicolucci, A., Rossi, M. C., D’Ostilio, D., Delbaere, A., de Portu, S., & Roze, S. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.03.011 · Cited by 16
Experiences of Adults Using Continuous Subcutaneous Insulin Infusion: A Qualitative Study
MESBAH, N., Taha, N., Rahme, Z. N., Sukkar, F., & Omar, D. (2019) · Medical Principles and Practice · doi:10.1159/000503705 · Cited by 15
Evidence for continuous glucose monitoring: sufficient for reimbursement?
Heinemann, L., & DeVries, J. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12341 · Cited by 14
Automated Insulin Delivery: The Artificial Pancreas Technical Challenges
Hernando, M. E., García-Sáez, G., Aguilera, E. J. G., Gandía, C. P., & Rodríguez-Herrero, A. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001086 · Cited by 17
The Impact of Technology on Current Diabetes Management
Garvey, K. C., & Wolfsdorf, J. I. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.005 · Cited by 16
Economic impact of hypoglycemia among insulin-treated patients with diabetes
Sussman, M. S., Sierra, J. A., Garg, S. K., Bode, B. W., Friedman, M., Gill, M., KAUFMAN, F. R., Vigersky, R. A., & Menzin, J. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1201090 · Cited by 17
Self-citationRisk analysis for the design of a safe artificial pancreas control system
Kölle, K., Fougner, A. L., Lundteigen, M. A., Carlsen, S. M., Ellingsen, R., & Stavdahl, Ø. (2018) · Health and Technology · doi:10.1007/s12553-018-0269-8 · Cited by 15
“The extended time spent in hyperglycemia during studies with threshold suspend systems [13] may be explained by this.”
BackgroundMusolino, G., Allen, J. M., Hartnell, S., Wilinska, M. E., Tauschmann, M., Boughton, C. K., Campbell, F., Denvir, L., Trevelyan, N., Wadwa, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027856 · Cited by 14
“Insulin pumps with low-glucose suspend feature have been shown to reduce hypoglycaemia.(13) These systems, however, overall provide little or no automation to adjust insulin delivery to match glucose excursions.”
Graf, A., McAuley, S. A., Sims, C. M., Ulloa, J., Jenkins, A. J., Voskanyan, G. R., & O'Neal, D. N. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816682762 · Cited by 15
Insulin Pump Therapy With Automated Insulin Suspension: Toward Freedom From Nocturnal Hypoglycemia
Choudhary, P. (2013) · JAMA · doi:10.1001/jama.2013.278576 · Cited by 15
Hypoglycemia in Diabetes: Does Insulin Type Matter?
Seaquist, E. R., & Chow, L. S. (2017) · JAMA · doi:10.1001/jama.2017.8075 · Cited by 14
Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
“pend insulin pump therapy) represents the simplest form of closed-loop insulin therapy [30].”
BackgroundSensor-augmented CSII therapy with predictive low-glucose suspend following total pancreatectomy
SCOTT, E. S., Fulcher, G. R., & Clifton-Bligh, R. J. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0093 · Cited by 14
Corathers, S. D., & DeSalvo, D. J. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0017 · Cited by 15
Schöttler, H., Auzanneau, M., Best, F., Braune, K., Freff, M., Heidtmann, B., Jung, R., Karges, B., Klee, D., Müller, A., et al. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1259-1190 · Cited by 15
“[25] Bergenstal RM, Klonoff DC, Garg SK et al.”
BackgroundNamikawa, T., Munekage, M., Yatabe, T., Kitagawa, H., & Hanazaki, K. (2018) · Journal of Artificial Organs · doi:10.1007/s10047-018-1019-4 · Cited by 13
Ang, K. H., Tamborlane, W. V., & WEINZIMER, S. A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1074174 · Cited by 13
“Threshold suspend pumps have been shown to reduce exposure to hypoglycemia, without increasing exposure to hyperglycemia [1]; these devices are now commercially available and in widespread use.”
Lega, I. C., Yale, J.-F., Chadha, A., Paty, B., Roscoe, R., Snider, M., Steier, J., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.003 · Cited by 12
Alternative therapeutic strategies in diabetes management
Annicchiarico, A., Barile, B., Buccoliero, C., Nicchia, G. P., & Brunetti, G. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1142 · Cited by 14
Weiss, R., Garg, S. K., Bergenstal, R. M., Klonoff, D. C., Bode, B. W., Bailey, T. S., Thrasher, J. R., Schwartz, F., Welsh, J. B., KAUFMAN, F. R., et al. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815586014 · Cited by 12
“The ASPIRE In-Home study (NCT01497938) was a randomized controlled trial of 247 patients with type 1 diabetes in which 121 were allocated to the TS group and 126 to the control group; the former group realized significant reductions in nocturnal hypoglycemia.(1) The strategy has also been evaluated in retrospective an…”
Self-citationAutomated Insulin Delivery—The Light at the End of the Tunnel
Turksoy, K., Frantz, N., Quinn, L., Dumin, M., Kilkus, J. M., Hibner, B. A., Çınar, A., & Littlejohn, E. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.02.055 · Cited by 14
Irace, C., Cutruzzolà, A., Tweden, K. S., & KAUFMAN, F. R. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1982380 · Cited by 14
“insulin pump therapy, studies have been reported with openloop insulin pump treatment [2], as well as with integrated closed-loop systems using automated insulin delivery [3].”
MethodSelf-citationGrosman, B., Parikh, N., Roy, A., LINTEREUR, L. J., Vigersky, R. A., Cohen, O., & Rhinehart, A. S. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-03079-9 · Cited by 13
Leelarathna, L., Dellweg, S., Mader, J. K., Barnard, K. D., Benesch, C., Ellmerer, M., Heinemann, L., Kojzar, H., Thabit, H., Wilinska, M. E., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006075 · Cited by 14
Hypoglycaemia, a global cause for concern
Heller, S. R., Amiel, S. A., & Khunti, K. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.11.004 · Cited by 12
“Data emerging from recent clinical trials have generally given the impression that rates of severe hypoglycaemia in both types of diabetes are steadily falling [1,2] and that, for T1D, they are now much lower than in the landmark Diabetes Control and Complications Trial [3], completed over 20 years ago.”
BackgroundResultPetruželková, L., Picková, K., Šumník, Z., Šoupal, J., & Obermannová, B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0459 · Cited by 12
“13,14 Published studies provided evidence that the LGS algorithm reduces the frequency of hypoglycemia in children and adolescents with type 1 diabetes under real-life conditions.”
Hirsch, I. B., Nardacci, E., & Verderese, C. A. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0059 · Cited by 14
Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies
Klonoff, D. C., Fleming, G. A., Muchmore, D. B., & Frier, B. M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2883 · Cited by 11
Self-citationSperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Garden, G. L., Fan, K. S., Paterson, M., Shojaee‐Moradie, F., Inguanez, M. B., Manoli, A., Edwards, V., Lee, V., Frier, B. M., Hutchison, E. J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06295-1 · Cited by 13
An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 Diabetes
Bode, B. W., KAUFMAN, F. R., & Vint, N. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0354 · Cited by 12
Self-citationMartín-Vaquero, P., Martínez‐Brocca, M. A., & López, J. M. G. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.08.003 · Cited by 13
Artificial Pancreas Technology Offers Hope for Childhood Diabetes
Schoelwer, M. J., & DeBoer, M. D. (2021) · Current Nutrition Reports · doi:10.1007/s13668-020-00347-9 · Cited by 11
Roze, S., Smith‐Palmer, J., Portu, S. D., Delbaere, A., Brouwer, B. D., & de Valk, H. W. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s186298 · Cited by 13
Aleppo, G., Parkin, C. G., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., Umpierrez, G. E., Forlenza, G. P., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0196 · Cited by 11
Technology to Reduce Hypoglycemia
Yeoh, E. C. K., & Choudhary, P. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815574547 · Cited by 12
Continuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Management of Adults with Type 1 Diabetes: Current Status and Suggestions
Jin, S., & Kim, J. H. (2014) · Journal of Korean Diabetes · doi:10.4093/jkd.2014.15.1.1 · Cited by 10
Thomas, A., Shin, J., Jiang, B., McMahon, C., Kolassa, R., & Vigersky, R. A. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817721242 · Cited by 11
“We used the existing CGM data from the ASPIRE In-Home trial to assess the new metrics and then compared them to the standard hypoglycemic metrics as reported in that study.(7) The design and results of this trial have been previously reported.”
MethodAbraham, M. B., Heels, K., Nicholas, J. A., Cole, C., Gebert, R., Klimek, J., Jopling, T., Ambler, G. R., Cameron, F. J., Davis, E. A., et al. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817752188 · Cited by 11
“Australia: Tenele Smith, Amy Crawford, Jordan Rafferty, Dr Bruce King; (4) Department of Endocrinology and Diabetes, Women’s and Children’s Hospital, Adelaide, Australia: Tania”
BackgroundKatayama, A., Tone, A., Watanabe, M., Teshigawara, S., Miyamoto, S., Eguchi, J., Nakatsuka, A., Shikata, K., & Wada, J. (2019) · Diabetology International · doi:10.1007/s13340-019-00408-7 · Cited by 10
Algorithmic literacy in medical students – results of a knowledge test conducted in Germany
Kampa, P., & Balzer, F. (2021) · Health Information & Libraries Journal · doi:10.1111/hir.12392 · Cited by 10
Predictive Low-Glucose Suspend to Prevent Hypoglycemia
Pinsker, J. E., & Dassau, E. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0064 · Cited by 11
Global research trends in AI-assisted blood glucose management: a bibliometric study
Li, Y., Wang, Y., Xing, M., Liu, T., & Xiang, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1579640 · Cited by 12
“Prominent authors from clinical, engineering, and computer science backgrounds have formed robust collaborative clusters, underscoring the importance of cross ‐ disciplinary efforts in addressing the complex challenges of diabetes care (16, 17).”
Martín-Vaquero, P., Martínez‐Brocca, M. A., & López, J. M. G. (2014) · Avances en Diabetología · doi:10.1016/j.avdiab.2014.07.002 · Cited by 13
NUEVAS TECNOLOGÿAS EN DIABETES
Apablaza, P., Néstor Soto, I., Román, R., & Ethel Codner, D. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.011 · Cited by 12
de Valk, H. W., Lablanche, S., Bosi, E., Choudhary, P., Silva, J. D., Castañeda, J., Vorrink, L., de Portu, S., & Cohen, O. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0222 · Cited by 9
“4–6 The development of these automated insulin delivery systems necessitates studies to demonstrate both their clinical effectiveness and their economic value, but the design of such studies is challenging.”
Basal insulin delivery reduction for exercise in type 1 diabetes: finding the sweet spot
Thabit, H., & Leelarathna, L. (2016) · Diabetologia · doi:10.1007/s00125-016-4010-8 · Cited by 9
“management [10], intermittent high intensity exercise or acute caffeine ingestion [11], may help uncover management approaches best suited for individuals with a”
Background
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.